Abstract: A wearable robot, system and method are provided for correcting gait impairments, such as knee hyperextension, in a user. The wearable robot is an assistive lower-limb exoskeleton having a frame and an actuation system to generate an assistive force with timing, duration, and amplitude based on a gait impairment mitigation strategy.

Abstract: A solution is proposed for performing authentications. A corresponding method comprises storing a verification string corresponding to applying a one-way function iteratively starting from a secret string. An authentication request is received in association with an authentication string (or more) being generated by applying the one-way function iteratively starting from the secret string for a lower number of times. A result of the authentication request is determined by comparing the verification string with a comparison string being generated by applying the one-way function to the authentication string (or a few times iteratively). Corresponding computer programs and a computer program products for performing the method are also proposed. Moreover, corresponding systems for implementing the method are proposed.

Abstract: A method, computer system, and a computer program product for brake detection is provided. The present invention may include determining a first geometric ratio associated with a rear portion of a first vehicle, from a first image of the first vehicle. The present invention may also include determining a second geometric ratio associated with the rear portion of the first vehicle, from a second image of the first vehicle. The present invention may further include, in response to determining that the second geometric ratio is less than the first geometric ratio, detecting a braking action of the first vehicle.

Abstract: Controlling communication handovers of a client computing device among a plurality of wireless networks providing access to a service network includes monitoring, by the client computing device, corresponding program usage information relating to the access to the service network of one or more software programs installed on the client computing device. The client computing device determines criticality indicators of the one or more software programs according to the corresponding program usage information and detects one or more wireless networks available for a current handover from a current wireless network to which the client computing device is currently connected. The client computing device controls the current handover from the current wireless network to a selected wireless network from the plurality of available wireless networks according to the criticality indicators of the one or more software programs currently running on the client computing device.

Abstract: A solution is proposed for performing authentications. A corresponding method comprises storing a verification string corresponding to applying a one-way function iteratively starting from a secret string. An authentication request is received in association with an authentication string (or more) being generated by applying the one-way function iteratively starting from the secret string for a lower number of times. A result of the authentication request is determined by comparing the verification string with a comparison string being generated by applying the one-way function to the authentication string (or a few times iteratively). Corresponding computer programs and a computer program products for performing the method are also proposed. Moreover, corresponding systems for implementing the method are proposed.

Abstract: Disclosed are solid oral controlled-release pharmaceutical compositions of antibiotics/ antibacterials comprising a core consisting of a complex monolithic matrix comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers. The compositions of the invention enable the frequency of administration to be reduced, and the release of the medicament in particular sites of the gastrointestinal tract to be controlled.

Abstract: A device and method for displaying security information to a user is provided. The present invention may include a security device configured to display a security information on a display surface. The security information may include at least one component having two images based on a splitting of its representation that are viewable from corresponding angles of view. The images may be fused into the representation of the at least one component by a visual system of the user looking at them at a reading distance causing the eyes of the user to look at the images from the corresponding angles of view. A corresponding method for displaying security information to a user is also provided.

Abstract: A solution is proposed for controlling access to computing resources. A corresponding method comprises receiving and verifying an access request for accessing the computing resources by a secondary computing environment (isolated from the computing resources). A main computing environment (isolated from the secondary computing environment) detects an indication of a positive result of the verification of the access request; in response thereto, the main computing environment verifies an integrity condition of the secondary computing environment and then authorizes the secondary computing environment to access the computing resources accordingly. A computer program and a computer program product for performing the method are also proposed. Moreover, a system for implementing the method is proposed.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Abstract: The present invention relates to solid oral pharmaceutical compositions for chronotropic administration of sartans, consisting of a monolithic matrix core comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac and an outer coating of said core consisting of a layer comprising ethyl cellulose, a gastroresistant layer, or a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

Abstract: The present invention relates to solid oral pharmaceutical compositions for chronotropic administration of dipeptidyl peptidase IV inhibitors consisting of a monolithic matrix core comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate or shellac and an outer coating of said core consisting of a layer comprising ethylcellulose, a gastroresistant layer, or a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

Abstract: The present invention relates to solid oral pharmaceutical compositions for chronotropic administration of mesalazine, the salts or derivatives thereof, consisting of a complex monolithic matrix core comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

Abstract: The present invention relates to solid oral controlled-release pharmaceutical compositions comprising a core consisting of a complex monolithic matrix comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

Abstract: The present invention relates to highly stable drug dosage forms comprising. The invention also contemplates said highly stable drug dosage forms for the treatment of diseases where inhibition of 4-hydroxyphenylpyruvate dioxygenase 5 will result at improving the health of the patient.

Abstract: Approaches for generating an alert in an absence of a radio-frequency identification (RFID) tag in proximity to a mobile device are provided herein. RFID tags are detected in proximity to the first mobile device, which has a RFID receiver. The alert is generated in response to alert conditions, including a determination that a RFID tag identifier stored in a first profile list is not among detected RFID tags and that an RFID tag stored in the first profile list is not in proximity to a second device. The alert is transmitted to the second mobile device, wherein the alert adds, responsive to the stored RFID tag not being among the detected RFID tags at the first device, the stored RFID tag to a second profile list associated with the second mobile device for storing RFID tag identifiers, wherein the second profile list is separate from the first profile list.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Abstract: A method for generating an alert on a mobile device in an absence of a radio-frequency identification (RFID) tag in proximity to the mobile device is provided herein. The method comprises defining an event. A profile list for storing RFID tag identifiers is related to the event. The method also comprises sharing the event data together with the profile list using a social media network, storing all received RFID tag identifiers at a time within the duration of the event after an event start time in the profile list if the profile list was empty before the event start time, and generating the alert under alert conditions. The alert conditions comprise a determination that the profile list was not empty before the event start time, and that one RFID tag identifier stored in the profile list is not among the received RFID tag identifiers during the event duration after the event time.

Abstract: Approaches for generating an alert in an absence of a radio-frequency identification (RFID) tag in proximity to a mobile device are provided herein. RFID tags are detected in proximity to the first mobile device, which has a RFID receiver. The alert is generated in response to alert conditions, including a determination that a RFID tag identifier stored in a first profile list is not among detected RFID tags and that an RFID tag stored in the first profile list is not in proximity to a second device. The alert is transmitted to the second mobile device, wherein the alert adds, responsive to the stored RFID tag not being among the detected RFID tags at the first device, the stored RFID tag to a second profile list associated with the second mobile device for storing RFID tag identifiers, wherein the second profile list is separate from the first profile list.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.